Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Altamira Therapeutics Ltd Altamira Therapeutics Provides Update on Nasdaq Listing October 04, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray September 27, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results September 24, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 September 20, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering September 19, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering September 17, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia September 16, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 September 03, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark August 23, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances August 16, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models August 12, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles July 19, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management June 20, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Provides Business Update May 28, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal May 23, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation May 01, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal April 24, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results April 10, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 April 04, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines March 25, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal February 07, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment January 24, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit January 08, 2024 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement December 29, 2023 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Provides Investor and Business Update December 11, 2023 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics to Host Investor & Business Update Call on December 11th December 05, 2023 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement November 29, 2023 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business November 17, 2023 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine November 10, 2023 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis September 14, 2023 From Altamira Therapeutics Ltd Via GlobeNewswire Tickers CYTO Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.